Osteopaenia - a marker of low bone mass and fracture risk by Pasco, J.A. & Kotowicz, M.A.
Critical review
Page 1 of 5
Co
m
pe
tin
g 
in
te
re
st
s:
 n
on
e 
de
cl
ar
ed
. C
on
fli
ct
 o
f I
nt
er
es
ts
: d
ec
la
re
d 
in
 th
e 
ar
tic
le
.
A
ll 
au
th
or
s 
co
nt
rib
ut
ed
 to
 th
e 
co
nc
ep
tio
n,
 d
es
ig
n,
 a
nd
 p
re
pa
ra
tio
n 
of
 th
e 
m
an
us
cr
ip
t,
 a
s 
w
el
l a
s 
re
ad
 a
nd
 a
pp
ro
ve
d 
th
e 
fin
al
 m
an
us
cr
ip
t.
A
ll 
au
th
or
s 
ab
id
e 
by
 th
e 
A
ss
oc
ia
tio
n 
fo
r M
ed
ic
al
 E
th
ic
s 
(A
M
E)
 e
th
ic
al
 ru
le
s 
of
 d
is
cl
os
ur
e.
Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY)
FĔė ĈĎęĆęĎĔē ĕĚėĕĔĘĊĘ: Pasco JA, Kotowicz MA. Osteopenia – a marker of low bone mass and fracture risk. Hard Tissue 
2013 Feb 22;2(1):10.
Osteopaenia – a marker of low bone mass and fracture risk
JA Pasco1,2*, MA Kotowicz1,2
Abstract
Areal bone mineral density is 
commonly categorised into normal 
bone mineral density, osteopaenia 
and osteoporosis on the basis of 
nominal thresholds recommended 
by the World Health Organization. 
However, bone mineral density is a 
continuous variable and there is a 
strong association between lower 
bone mineral density and greater 
risk for fracture. Fracture risk is not 
negligible in persons with moderate 
deficits in bone mineral density. 
Although absolute fracture risk is 
greatest for individuals with osteopo-
rosis, more than half of the fractures 
arise from those with osteopaenia, 
and even normal bone mineral 
density, a probable consequence of 
greater numbers of individuals at 
risk in these categories. However, 
areal bone mineral density meas-
urements used commonly in clinical 
practice do not detect differences in 
bone tissue properties, geometry and 
microarchitecture, which contribute 
to bone strength. Newer technolo-
gies such as high-resolution periph-
eral computed tomography have the 
advantage of assessing trabecular 
and cortical components of bone 
separately, in addition to geometric 
characteristics of the skeleton. Quan-
tifying these parameters and consid-
ering clinical risk factors that affect 
fracture risk independent of bone 
quantity and quality, may better 
discriminate between high- and low-
risk individuals. This would improve 
the decision-making for targeting 
appropriate interventions, either 
lifestyle or medication, to reduce the 
public health burden of fractures.
Introduction
Deϔining osteopaenia and 
 osteoporosis
For nearly three decades, areal bone 
mineral density (BMD) has been 
measured using either dual-photon 
absorptiometry or, more recently, 
dual-energy X-ray absorptiometry 
(DXA) as a marker of osteoporosis1. 
DXA-derived BMD is calculated as 
the bone mineral content divided 
by the area of bone scanned. This 
two-dimensional representation 
of  volumetric BMD is confounded 
by bone size and shape. Nonethe-
less, fracture risk increases with 
decreasing BMD, such that each 
standard deviation decrease in BMD 
is associated with a 1.5–3.0-fold 
increase in age-adjusted fracture 
risk2.
BMD is a continuous variable, 
which approximates a normal distri-
bution, and it is commonly catego-
rised into normal BMD, osteopaenia 
and osteoporosis on the basis of 
nominal thresholds recommended 
by an expert panel of the World 
Health Organization3. Osteopaenia is 
the low bone mass category defined 
by BMD T-scores between −1.0 and 
−2.5. Using these cut-points, 16% of 
young normal women are defined 
as having osteopaenia and 5% have 
osteoporosis, but these individuals 
may make little, if any, contribution to 
the population burden fragility frac-
ture. The osteopaenia threshold was 
based on data that derived a theoret-
ical fracture threshold4, whereas the 
osteoporosis threshold was based 
on the prevalence of fracture among 
postmenopausal Caucasian women. 
Although these thresholds were 
devised for epidemiological purposes 
appropriate for Caucasian women, 
they have been widely adopted for 
clinical use in broader populations. 
Almost half of women aged 50 
years and older in Australia have 
osteopaenia (and 23% have osteo-
porosis corresponding to BMD 
T-score < −2.5)5. Although thresh-
olds for describing men with normal 
BMD, osteopaenia and osteoporosis 
have not been defined, the gradient 
for fracture risk is similar for each 
standard deviation deficit in BMD for 
both sexes. Utilising similar T-score 
thresholds for men aged 50 years 
and older indicates that just over half 
have osteopaenia corresponding to 
BMD T-score from −1.0 to −2.5 (and 
6% have osteoporosis, T-score < 
−2.5)5. As there is discordance in BMD 
between skeletal sites, such estimates 
depend on the site scanned, as well as 
the reference range used to determine 
T-scores6,7. However, while osteopo-
rosis confers the greatest risk for frac-
ture, fracture risk is not negligible in 
persons with more moderate deficits 
in BMD8–10. Age-standardised 5-year 
absolute fracture risk derived from 
total hip BMD at baseline for post-
menopausal women in Australia are 
30.8% (95%CI 22.0–39.6) for women 
with osteoporosis, 17.5% (95%CI 
13.2–21.7) for women with osteo-
paenia and 7.2% (95%CI 3.7–10.7) 
for women with normal BMD8.
Fracture and BMD
Population-based studies reveal 
that the burden of fracture arises, 
not from the relatively small, high-
risk group with osteoporosis, but 
from the larger group with inter-
mediate risk. Different studies have 
used different inclusion and exclu-
sion criteria, defined low-trauma 
fractures in different ways and 
ascertained different combina-
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tions of fractures as the outcome. 
Based on proximal femur BMD from 
a  population-based cohort study 
of 616 postmenopausal Australian 
women followed for 5.6 years, 26.9% 
of radiologically confirmed fractures 
arose from women with osteoporosis 
and 73.1% from women without 
osteoporosis (56.5% from women 
with osteopaenia and 16.6% from 
women with normal BMD measured 
at the total hip)8.
Similarly, in a cohort study of 
149,524 postmenopausal white 
women enrolled in National Osteo-
porosis Risk Assessment (NORA) 
from primary care practices in the 
United States and followed for 12 
months after baseline assessment 
using BMD measurements obtained 
from a variety of peripheral devices 
(heel, finger or forearm), 18% of 
self-reported fractures arose from 
women with osteoporosis and 82% 
from women without osteoporosis 
(52% from women with osteopaenia 
and 30% from women with normal 
BMD)10.
The NORA data excluded those 
with a history of known osteopo-
rosis or anti-fracture therapy and 
this may explain the difference in the 
proportion of fractures arising from 
each BMD category between the 
Australian and US studies. Further-
more, the prevalence of osteoporosis 
and osteopaenia varies depending on 
the device, the site of BMD measure-
ment and the reference population 
used to define T-scores. Same-site 
differences exist, not only between 
machines from the same manufac-
turer, but also across devices made 
by different manufacturers11; periph-
eral devices generate T-scores that 
may differ from those derived using 
hip or spine DXA12 and the choice 
of reference population impacts on 
the BMD cut-points for identifying 
osteopaenia and osteoporosis6. The 
Geelong Osteoporosis Study (GOS) 
data used proximal femur BMD 
because of the well-recognised influ-
ence of age-related artefacts on spine 
BMD measurements13. However, 
despite these methodological limita-
tions, greater numbers of fractures 
are consistently shown to arise 
in women with normal or osteo-
paenic BMD and this may simply be 
a  consequence of larger numbers of 
women at risk of fracture in these 
groups (Figure 1).
However, the risk for fracture is 
multi-factorial. Many clinical risk 
factors for fracture operate through 
reduced BMD; however, others act 
independent of BMD14. Increasing 
age contributes independently to the 
risk of fracture; for the same BMD, 
the risk of fracture varies by a factor 
of 8–10 between women aged <45 
years and 80 years and older15. Even 
though the majority of individuals 
who sustain a fragility fracture do 
not have a prevalent fracture (this 
proportion is 75% among women 
with osteopaenia), a prior fracture 
independently doubles the risk of 
subsequent fracture; women with 
osteopaenia and a prevalent frac-
ture are at comparable risk to those 
with osteoporosis on BMD criteria8. 
Low body mass index is recognised 
as a risk factor for fracture that is 
essentially independent of age and 
sex, but dependent on BMD16. Falls 
independently increase the risk of 
 fracture8,17,18. 
Fracture risk assessment
Various models for predicting frac-
ture have been developed that involve 
BMD in conjunction with clinical risk 
factors with an aim of improving risk 
stratification, particularly within 
the large group with moderate bone 
deficits categorised as osteopaenia. 
The World Health Organization 
collaborating centre developed the 
FRAX algorithm as a tool based on 
clinical risk factors, with and without 
BMD, using primary data from 
multi-national prospective cohort 
studies19,20. The FRAX estimates 
10-year probability of hip fractures 
and major osteoporotic fractures 
(including fractures of the hip, spine, 
humerus and wrist).
In Australia, data from two popula-
tion-based studies, the GOS21 and the 
Dubbo Osteoporosis Epidemiology 
Study independently combined BMD 
and clinical risk factors to generate 
fracture risk assessment tools known 
Figure 1: The distribution of bone mineral density (BMD) at the total hip for women 
is shown, together with the cut-off points for osteoporosis and osteopaenia (shaded 
in grey). Absolute risk for fracture (%) is represented by the unshaded columns, indi-
cating that absolute risk for the group with osteopaenia is intermediate between those 
with osteoporosis and normal BMD. The proportion of fractures arising from those with 
osteoporosis, osteopaenia and normal BMD is represented by columns shaded in black, 
indicating that most fractures arise from the group with osteopaenia. Data relate to post-
menopausal Australian women8.
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as the GOS Fracture Risk (FRISK) 
Score17,22 and the Garvan algorithm23, 
respectively. The GOS FRISK esti-
mated 10-year probability of low-
trauma fractures at the hip, spine, 
forearm and humerus, whereas the 
Garvan predicted 5- and 10-year 
probability of fragility fractures of 
the hip, spine, wrist, humerus, hand, 
scapula, clavicle, pelvis, lower limb 
and sternum. The FRAX includes 
multiple clinical risk factors, whereas 
both the GOS FRISK and Garvan utilise 
fewer risk factors (Table 1). The FRAX 
did not include falls because these 
data were not consistently collected 
across the multiple population-based 
studies from which the data were 
derived14. The purpose of developing 
such models is to provide clinically 
useful tools to better identify, with 
high sensitivity and specificity, indi-
viduals in the population who are at 
greatest risk for fracture.
Bone microarchitecture and 
structure
The observation that age and 
previous fracture independently 
increase the risk for fracture8,17 
is consistent with the notion that 
increasing age24 and fragility frac-
ture25 are markers for greater mate-
rial or structural deterioration in 
bone, not quantified by BMD. Bone 
morphology and microarchitecture 
contribute to the breaking strength 
of bone26. To be strong, bones need 
to be stiff enough to withstand 
deformation under loading, yet 
adequately elastic to absorb energy 
during compression and tension27. 
Recently developed technologies 
for assessing bone structure include 
high-resolution peripheral quantita-
tive computed tomography (pQCT) 
and magnetic resonance imaging that 
have the advantage of simultaneously 
assessing trabecular and cortical 
components of bone separately, in 
addition to geometric characteristics 
of the peripheral skeleton28,29.
In a matched case–control study of 
postmenopausal French women, 101 
cases with fragility fracture over 13 
years of follow-up were matched with 
fracture-free controls30. Vertebral and 
non-vertebral fractures were associ-
ated with low volumetric BMD and 
structural deterioration of trabecular 
and cortical bone as assessed by 
high-resolution pQCT at the distal 
radius and tibia, independent of areal 
BMD. Cases had decreased trabecular 
volume, cortical thickness, trabec-
ular number and trabecular thick-
ness. Similarly, in another study 
using high-resolution pQCT, osteo-
porotic women had lower density, 
cortical thickness and increased 
trabecular separation than osteo-
paenic women. Among osteopaenic 
women, those with fracture had 
lower trabecular density and more 
heterogeneous trabecular distribu-
tion25. These women were defined as 
having osteoporosis or osteopaenia 
based on measurements of BMD at 
the lumbar spine or proximal femur. 
The lower T-score was used to cate-
gorise subjects. A proportion of those 
with BMD in the osteopaenic range 
at the lumbar spine, alone, are likely 
to have had osteoporosis with the 
BMD measurement being spuriously 
increased by artefact. The apparent 
greater micro-architectural dete-
rioration among those women with 
osteopaenia and fracture may there-
fore have been related to miscatego-
risation.
The pQCT assessment of the 
ultradistal radius in the United States 
shows that the structural basis for 
the observed decrease in trabec-
ular volume differs between men 
and women. With ageing, women 
undergo loss of trabeculae with an 
increase in trabecular separation, 
whereas men start with thicker 
trabeculae and experience less age-
related microstructural damage. 
Because decreases in trabecular 
number substantially affect bone 
strength, this finding may explain, 
at least in part, the protection men 
have against age-related increases in 
distal forearm fractures. More recent 
findings suggest that development 
of intracortical porosity may play 
an important role in compromising 
bone strength24,31 and that this could 
explain the high proportion of non-
Table 1. Clinical risk factors incorporated into the fracture risk predicƟ on 
 models, FRAX19,20, Garvan23 and FRISK17,22.
FRAX Garvan FRISK
BMD femoral neck BMD femoral neck or weight BMD femoral neck
BMD spine
Age Age
Gender Gender (Women only)
Weight, height (or BMI) Weight
Previous fracture Previous fracture Previous fracture
Falls Falls
Parent fractured hip
Current smoking
Oral glucocorƟ coid use
Rheumatoid arthriƟ s
Other secondary 
 causes of osteoporosis*
Alcohol 3 or more units 
per day
*  Chronic liver disease, untreated hypogonadism, prolonged immobility, organ trans-
plantation, type 1 diabetes, thyroid disorders, gastrointestinal disease.
 BMD, bone mineral density; BMI, body mass index; FRISK, Fracture Risk.
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vertebral fractures that occur with 
ageing at predominantly cortical 
sites24.
In an Australian study of 185 
female twin pairs aged 40–61 years, 
postmenopausal women were found 
to have higher levels of remodel-
ling markers that were associated 
with larger intracortical surface 
area rather than with the progres-
sively diminishing trabecular surface 
area31. Identification of intracortical, 
endocortical and trabecular bone 
surface area are beyond the resolu-
tion of contemporary DXA analysis 
and are, therefore, not accounted for 
using BMD from DXA.
Conclusion
Fragility fractures pose a consider-
able health burden to the commu-
nity. Effective strategies to reduce the 
burden of fractures depend on the 
development of preventive measures 
to target lifestyle or pharmacological 
interventions, based on identification 
of individuals at risk. The burden of 
fractures arises, not from the rela-
tive few with severely low BMD 
 identified as osteoporosis, but from 
those with mild to moderate bone 
deficits. Individuals with osteopaenia 
are commonly not treated because 
there is a lack of data relating to 
anti-fracture therapies in this group 
and, based on post hoc analyses 
from osteoporosis clinical trials, the 
numbers needed to treat are too 
large to be economically feasible if 
the whole group is to be considered. 
Yet, over half of the fractures in the 
population arise from this group. 
Those at highest risk for fracture 
within this group need to be identi-
fied and evidence-based treatment 
strategies developed to reduce the 
public health burden of fractures.
Improved risk stratification may 
be achieved by quantifying factors 
that contribute to bone strength, 
such as bone morphology and micro-
architecture, which are properties 
beyond the resolution of conven-
tional densitometry by DXA. It needs 
to be demonstrated that such predic-
tors of risk are amenable to reduction 
with osteoporosis therapies and that 
anti-fracture treatment reduces frac-
ture risk before recommendations 
are deemed appropriate. Further-
more, non-bone risk factors, that are 
amenable to modification, also need 
to be considered.
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